BNT162b2 mRNA Vaccination Against COVID-19 is Associated with Decreased Likelihood of Multisystem Inflammatory Syndrome in U.S. Children Ages 5-18 Years.
Laura D ZambranoMargaret M NewhamsSamantha M OlsonNatasha B HalasaAshley M PriceAmber O OrzelCameron C YoungJulie A BoomLeila C SahniAline B MadduxKatherine E BlineSatoshi KamidaniKeiko M TarquinioKathleen ChiotosJennifer E SchusterMelissa L CullimoreSabrina M HeidemannCharlotte V HobbsRyan A NofzigerPia S PannarajMelissa A CameronTracie C WalkerStephanie P SchwartzKelly N MichelsonBria M CoatesHeidi R FloriElizabeth H MackLaura SmallcombShira J GertzSamina S BhumbraTamara T BradfordEmily R LevyMichele KongKatherine IrbyNatalie Z CvijanovichMatt S ZinterCindy BowensHillary CrandallJanet R HumeManish M PatelAngela P CampbellAdrienne G Randolphnull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
Vaccination with two doses of BNT162b2 is associated with reduced likelihood of MIS-C in children ages 5-18 years. Most vaccine eligible hospitalized patients with MIS-C were unvaccinated.